Clinical Outcome

Home / Clinical Outcome


HOO-IMM PLUS-B Polyherbal Formulation Consists Of Number of Active Molecules Of Different Plant Species that Act On Multiple Targets Against HBV.

1) Betulinic Acid, Elagic Acid and Mastic gum prevents the progression of Hepato Carcino genesis. Inhibits proliferation induces apoptosis, potentiate attenuate ROS.
2) Mastic gum and Sesquiterpenoid Glycosides significantly reduces serum HBV (a marker of efficacy) as well as HBeAg (a marker of viral replication) indicating inactivity of the virus and low infectivity.
3) Elagic Acid & Betulinic Acid improves the level of liver enzymes, protects against liver injury due to HBV, significantly increase the anti- oxidant activity protecting acute hepatotoxicity.


Quantification of HBV reflects the viral load which plays a critical role in determining the phase of infection, deciding the treatment and determining the response to anti-viral treatment.

Case 1: Patient dropped Anti-viral drug (TDF) In this present study, HBV patients receiving conventional Anti-viral drug (TDF) had to drop the treatment due to poor compliance (developing jaundice within the interval of 15 days and incidence of elevated SGPT & SGOT level) also virological relapse after cessation of Anti-viral drug (TDF) therapy. The patients discontinued the Anti-viral drug (TDF) therapy due to side effects and went on HOO-IMM PLUS-B therapy. Further the patient followed up every 3 months for monitoring and within the interval of 4-6 months HBV Quantitative level were monitored. After the cessation of Anti-viral drug (TDF) therapy for 21 days, the mean HBV level was 4.7 log IU/ml. With the follow up of HOO-IMM PLUS-B treatment in the first 6 months the mean HBV level was 3.5 log IU/ml and the treatment was continued for 12 months reported Target Not Detected for HBV Quantification.

Case 2: Drug naïve HBV individual receiving HOO-IMM PLUS-B In this present study, the patient never had any medication pertaining to HBV infection, received HOO-IMM PLUS B therapy, they showed good compliance and virological suppressions right after few weeks of treatment. The patients continued the therapy due to the viral decline in the first 4 month of the treatment. Furthermore they followed up for 12 months and they were monitored in the interval of 4 months. The mean HBV level initially found to be 4.5 log IU/ml that has been declined to mean 2.5 log IU/ml in the first 4 months of the treatment to mean 1.46 log IU/ml in the next 4 months of the treatment followed by Target Not Detected in the 12th month monitoring. Moreover, there is a regulated normal liver enzyme throughout the treatment.


Several Anti-Viral Those Are Currently Available For The Treatment Of HBV Which Includes IFN Alpha and Other ARVs.

Failed ARVs Treatment: Several anti-viral those are currently available for the treatment of HBV which includes IFN alpha and other ARVs. Interferon therapy has limited efficacy, slow acting and frequently causes adverse effect. Undesirable side effects of interferon treatment are found such as fever, malaise, fatigue, depression, hair loss, neutropenia and thrombocytopenia.

On the other hand the side effects of ARVs is no less than Interferon. The common side effects includes fever, pain, diarrhea, vomiting, depressed mood, rashes, insomnia. Moreover, the anti-viral drug and Interferon are expensive. Moreover, if the patient drops the ARVs medication even for 48 hours the HBV viral load elevates to 103.


The HOO-IMM PLUS-B constitute molecules which has been proven a star key molecule in preventing hepatocellular viral induced Carcinoma.

The HOO-IMM PLUS-B constitute molecules which has been proven a star key molecule in preventing hepatocellular carcinoma. Many research have been done on the molecule suggesting that it inhibits proliferation, induces apoptosis, potentiate attenuate ROS. But the poor systemic absorption of molecule is a major obstacle for its efficacy. Here we have a unique extraction procedure for the said molecule which yields high degree bioavailaibility and along with other herbal extract formulation that improves the gut absorption.

HOO-IMM PLUS-B induce Complete cure for HBV

Anti-HBs (Hepatitis B Surface antibody) is an antibody that the body naturally produces in response to the exposure against Hepatitis B Virus or vaccination against HBV. When the immune system recognizes the HBV surface antigen, it produces antibodies that bind to the antigen and neutralizes the virus. The antibodies (Anti-HBs) can also prevent future HBV infection.

Different trend of the person do not develop anti-HBs under the influence of Anti-viral drug (TDF). It has been found clinically the patient under the Anti-viral drug (TDF) influences do not develop anti-HBs naturally for even after years of treatment.

Although with the low HBV quant with Anti-viral (TDF) drug, the anti-HBs naturally developing antibodies have not been found against the absence of antigen since anti-HBs is an essential antibody to prevent body from future viral exposure or relapse. In such a case there is a loose end in successive HBV treatment.

On the contrary, HOO-IMM PLUS-B receiving patient develops anti-HBs for the existing viral exposure. The Anti-HBs response induced by HOO-IMM PLUS-B is much more detectable through commercially available anti-HBs test. For any drug-naive patient receiving therapy with HOO-IMM PLUS-B, there will be a noticeable rise in anti-HBs over time.

The patient under Anti-viral drug (TDF) along with HOO-IMM PLUS-B in order to develop anti-HBs the patient has to withdraw Anti-viral drug (TDF) and continue HOO-IMM PLUS-B alone for anti-HBs restoration.

Different bioactive compound of HOO-IMM PLUS-B targets different life activity of the virus apart from immune restoration to bring down the time duration for speedy recovery. It varies from patient to patient since the level of anti-HBs can vary depending on the severity and duration of the infection.

Normal Liver Function

Hooimm Plus Prevents Liver Injury From Viral Hepatitis. HBV Individuals Receiving Hooimm Plus Treatment Having Normalized Liver Enzyme.

Hooimm Plus B prevents liver injury from viral hepatitis. HBV individuals receiving Hooimm plus B treatment having normalized liver enzyme. The treatment prognosis reports normal level of the routine test of Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) and Aspartate Aminotransferase (AST). AST and SGPT is a blood test that checks for the liver damage. SGPT and AST levels in the blood rise if your liver is damaged.